- Home
- VERI vs IMUX Comparison
VERI vs IMUX Comparison
Compare VERI & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERI
- IMUX
- Stock Information
- Founded
- VERI 2014
- IMUX 2016
- Country
- VERI United States
- IMUX United States
- Employees
- VERI N/A
- IMUX N/A
- Industry
- VERI EDP Services
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- VERI Technology
- IMUX Health Care
- Exchange
- VERI Nasdaq
- IMUX Nasdaq
- Market Cap
- VERI 124.0M
- IMUX 102.2M
- IPO Year
- VERI 2017
- IMUX N/A
- Fundamental
- Price
- VERI $2.33
- IMUX $1.09
- Analyst Decision
- VERI Strong Buy
- IMUX Strong Buy
- Analyst Count
- VERI 2
- IMUX 7
- Target Price
- VERI $5.25
- IMUX $12.67
- AVG Volume (30 Days)
- VERI 398.0K
- IMUX 555.7K
- Earning Date
- VERI 03-13-2025
- IMUX 05-07-2025
- Dividend Yield
- VERI N/A
- IMUX N/A
- EPS Growth
- VERI N/A
- IMUX N/A
- EPS
- VERI N/A
- IMUX N/A
- Revenue
- VERI $92,637,000.00
- IMUX N/A
- Revenue This Year
- VERI $23.41
- IMUX N/A
- Revenue Next Year
- VERI $26.79
- IMUX N/A
- P/E Ratio
- VERI N/A
- IMUX N/A
- Revenue Growth
- VERI N/A
- IMUX N/A
- 52 Week Low
- VERI $2.03
- IMUX $0.92
- 52 Week High
- VERI $7.76
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- VERI 39.23
- IMUX 46.81
- Support Level
- VERI $2.60
- IMUX $1.18
- Resistance Level
- VERI $2.84
- IMUX $1.28
- Average True Range (ATR)
- VERI 0.19
- IMUX 0.07
- MACD
- VERI 0.00
- IMUX -0.00
- Stochastic Oscillator
- VERI 9.02
- IMUX 6.00
About VERI Veritone Inc.
Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has a presence in the United States, the United Kingdom, France, Australia, Israel and India.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.